FDA
-
-
-
-
-
-
-
Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
-
-
-
-
-
-
-
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
-
-
-
-
-
-
-
Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit
-
-
-
-
-
-
-
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
-
-
-
-
-
-
-
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
-
-
-
-
-
-
-
Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
-
-
-
-
-
-
-
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024
-
325,466 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

